Skip to content
ProPublica Donate
ProPublica Donate
New Search

Marksans Pharma Limited

India See location details
Last FDA Action: Apr 17, 2024

This drug manufacturing facility is registered with the FDA by Marksans Pharma Limited. ProPublica was able to identify at least 136 generic drugs that have been manufactured at this facility.

Facility Inspection History

The FDA is responsible for inspecting drug manufacturing facilities for violations of good manufacturing practices, such as a lack of documented drug quality testing or contaminated equipment. Below is a timeline of FDA inspections and outcomes for this facility assembled by ProPublica.

Note: ProPublica does not provide medical advice. Stopping your medication, doctors warn, can be dangerous. Please consult your doctor first if you have concerns. Read more
6 Known Inspections

The inspections we were able to locate using available FDA data do not include inspections in advance of the release of a new drug product.

4 Inspections Found Issues

When issues are observed, inspectors usually file an FDA 483 form with citations. In more serious cases, the FDA can issue warning letters or even ban the import of drugs from the facility.

  • Apr 17, 2024
    Apr 17, 2024
    Inspection With Issues

    The FDA found issues but determined the facility can correct them voluntarily.

    In some cases, inspectors may have recommended a different (potentially more serious) classification, but the agency declined to pursue further enforcement at the time.
    ProPublica was unable to locate a 483 form detailing issues found in this inspection.
  • Aug 4, 2023
    Aug 4, 2023
    Inspection With Issues

    The FDA found issues but determined the facility can correct them voluntarily.

    In some cases, inspectors may have recommended a different (potentially more serious) classification, but the agency declined to pursue further enforcement at the time.
    View Inspector Notes
    Inspector’s notes summarizing deficiencies observed during an inspection.
    2 citations
    Failure to submit ADE report
    Adverse drug experience information has not been reported to FDA.
    Failure to develop written procedures
    Written procedures have not been developed for the receipt and reporting to FDA of post marketing adverse drug experiences.
    View Inspector Notes
    Inspector’s notes summarizing deficiencies observed during an inspection.
  • Mar 5, 2019
    Mar 5, 2019

    An inspector documented issues at the facility.

    We were unable to connect this 483 form to an FDA inspection designation, but we do know that an inspector filed this form observing problem(s).
    View Inspector Notes
    Inspector’s notes summarizing deficiencies observed during an inspection.
    View Inspector Notes
    Inspector’s notes summarizing deficiencies observed during an inspection.
  • Apr 7, 2017
    Apr 7, 2017
    Inspection With Issues

    The FDA found issues but determined the facility can correct them voluntarily.

    In some cases, inspectors may have recommended a different (potentially more serious) classification, but the agency declined to pursue further enforcement at the time.
    ProPublica was unable to locate a 483 form detailing issues found in this inspection.
  • Sep 3, 2015
    Sep 3, 2015
    Inspection

    The FDA determined this facility was in an acceptable state.

    This is the best possible outcome for an inspection. The FDA took no compliance action and ProPublica found no issues documented by inspectors.
  • Aug 3, 2012
    Aug 3, 2012
    Inspection

    The FDA determined this facility was in an acceptable state.

    This is the best possible outcome for an inspection. The FDA took no compliance action and ProPublica found no issues documented by inspectors.
  • Nov 13, 2009
    Nov 13, 2009
    Inspection With Issues

    The FDA found issues but determined the facility can correct them voluntarily.

    In some cases, inspectors may have recommended a different (potentially more serious) classification, but the agency declined to pursue further enforcement at the time.
    ProPublica was unable to locate a 483 form detailing issues found in this inspection.

Drugs Manufactured Here

Below is a list of generic prescription drugs that we’ve been able to connect to this facility. Brand name and over-the-counter drugs, as well as labels we were unable to trace, are not included here.

Duloxetine

CompanyMarksans Pharma
Dosage
Duloxetine Hydrochloride
30mg
Blue capsule-shaped capsule, delayed release marked with RDY609 30mg
NDC: 25000-609-X

Duloxetine

CompanyMarksans Pharma
Dosage
Duloxetine Hydrochloride
60mg
Blue capsule-shaped capsule, delayed release marked with RDY610 60mg
NDC: 25000-610-X

Duloxetine

CompanyMarksans Pharma
Dosage
Duloxetine Hydrochloride
20mg
Green capsule-shaped capsule, delayed release marked with RDY608 20mg
NDC: 25000-608-06

Dutasteride

CompanyMarksans Pharma
Dosage
0.5mg
Light yellow capsule-shaped capsule, liquid filled marked with 11
NDC: 25000-011-X

Fluoxetine

CompanyTime Cap Laboratories
Dosage
Fluoxetine Hydrochloride
10mg
Light blue cap and light blue body capsule marked with FLUOXETINE10mg R147
NDC: 49483-701-X

Fluoxetine

CompanyTime Cap Laboratories
Dosage
Fluoxetine Hydrochloride
40mg
Light blue cap and white body, capsule marked with FLUOXETINE40mg R149
NDC: 49483-703-X

Fluoxetine

CompanyMarksans Pharma
Dosage
Fluoxetine Hydrochloride
20mg
Light blue cap and light torquoise blue body capsule marked with FLUOXETINE20mg R148
NDC: 25000-148-X

Fluoxetine

CompanyMarksans Pharma
Dosage
Fluoxetine Hydrochloride
40mg
Light blue cap and white body capsule marked with FLUOXETINE40mg R149
NDC: 25000-149-X

Fluoxetine

CompanyNorthwind Pharmaceuticals
Dosage
Fluoxetine Hydrochloride
40mg
Light blue cap and white body, capsule marked with FLUOXETINE40mg R149
NDC: 51655-081-26

Fluoxetine

CompanyTime Cap Laboratories
Dosage
Fluoxetine Hydrochloride
20mg
Light blue cap and light torquoise blue body capsule marked with FLUOXETINE20mg R148
NDC: 49483-702-X

Fluoxetine

CompanyMarksans Pharma
Dosage
Fluoxetine Hydrochloride
10mg
Light blue cap and light blue body capsule marked with FLUOXETINE10mg R147
NDC: 25000-147-X

Gabapentin

CompanySt. Mary’s Medical Park Pharmacy
Dosage
100mg
White capsule marked with 103
NDC: 60760-605-X

Frequently Asked Questions

What Do the Inspection Outcomes Mean?
These are the possible FDA compliance outcomes we highlight:
  • Import alert. This is rare and means drugs from this facility were banned from coming into the U.S. Specifically we are including alerts relating to FDA manufacturing standards for drug products. The agency sometimes exempts certain drugs from import bans, ostensibly to prevent drug shortages.
  • Warning letter. This is a disciplinary tool the FDA uses to lay out significant violations of federal requirements. The company has an opportunity to respond and/or provide its plans to correct the issues. The agency might later issue a “close-out letter” to say it has confirmed that issues raised in a previous warning letter were fixed. But that doesn’t always happen.
  • Unacceptable state of compliance. This means inspectors found serious issues at the facility and the agency ultimately recommended official compliance action. In cases like this, the FDA typically pauses the facility’s pending drug approvals. The agency classifies this as “official action indicated.”
  • Some issues found, but no further FDA action. This is very common. It means the FDA found issues but determined the facility can correct them voluntarily. In some cases, inspectors may have recommended a different (potentially more serious) classification, but the agency declined to pursue further enforcement at the time. The agency classifies this as “voluntary action indicated.”
  • Inspector documented issues. Inspectors can file notes summarizing deficiencies observed during an inspection using a 483 form. In some cases, we’re unable to connect a Form 483 to an FDA inspection designation, but we show that an inspector filed this form, perhaps as part of an inspection that was not included in the public inspection dashboard.
  • Acceptable state. This is common and the best possible outcome for an inspection. This means the FDA took no compliance action and ProPublica found no issues documented by inspectors. That doesn’t always mean no issues turned up. Sometimes, inspectors address concerns with management on site that they believe do not need to be documented on a 483. The agency classifies this as “no action indicated.”
There may be additional communications, including about issues being resolved, that are not reflected in our database because they have not been made public.

How Did ProPublica Connect This Information?
We have written an in-depth methodology, but in short, we connected several FDA databases:
  • The Structured Product Labeling database.
  • The National Drug Code Directory.
  • The Electronic Drug Registration and Listing System.
  • Data from the agency’s inspection dashboard.
  • A spreadsheet of facility addresses we sued the FDA for, which connected them to drug application numbers.
  • Form 483 documents we received from a Freedom of Information Act Request.
ProPublica described the app and the methodology used to build it to the FDA, which did not comment. The agency previously told ProPublica that it doesn’t reveal where drugs are made on inspection reports to protect what it deemed confidential commercial information.

How Do I Report Incorrect Information?
If you work for a manufacturer or otherwise see that information we are displaying may be incorrect, please email [email protected].